2013.09.16 Weekly Broadcast Email

The following updates were made to the CCCWF CCOP Research Base website for the week of September 16, 2013. 

  


13th Annual Meeting:

-
Final Week of Registration: Registration will close on Monday, September 23rd.

The CCCWF CCOP Research Base 13th Annual Meeting will be held October 24-26 in Asheville, NC.  Please visit our annual meeting website for the meeting agenda, accommodation information, and registrationWe look forward to seeing you in October!

  

-Invitation for sites participating in the Prevent Study (WFU, SCCC-Forsyth, Asheville, Charlotte, Upstate, Greenville, University of Miami and Wichita CCOPs) and any other interested parties:

On Saturday, October 26 at 7 a.m. you are invited to attend an investigator’s meeting for the “Preventing Anthracycline Cardiotoxicity with Statins” or PREVENT study. This study will look at the effect of statins on the cardiovascular health of women receiving anthracycline chemotherapy for Stage I-III breast cancer, and is set to begin recruiting this fall.

During this session, I will be providing an overview of the study design, followed by a review of the MRI protocol. This session will be essential for principal investigators, on-site project managers, physicians involved in MRI, and MRI technicians from the participating CCOP sites. Any CCOP staff are also welcome to attend and engage in this discussion and question and answer session.

I look forward to meeting with all of you as we move closer to the opening of this protocol. See you in October.

Sincerely,


W. Gregory Hundley, M.D.

Principal Investigator, PREVENT study

Professor of Internal Medicine (Cardiology) and Radiology

Wake Forest University School of Medicine

Winston-Salem, NC


98213:
(Preventing Anthracycline Cardiovascular Toxicity with Statins (PREVENT))

The study documents have been posted to the
website. This study is not open to accrual. The documents are made available for participating sites to prepare for study activation and training. The participating sites are WFU, SCCC-Forsyth, Charlotte, and Asheville, Upstate, Greenville, University of Miami and Wichita CCOPs.

  


91105:
(Phase III Double Blind, Placebo Controlled Study of Donepezil in Irradiated Brain Tumor Patients)

The 2013 Continuing Review approval letter has been added to the archived amendment page.

   

Thank you

  

Sarah C. Hahne, CCRP

Protocol Information Office

CCCWFU CCOP Research Base

Wake Forest University School of Medicine

Medical Center Boulevard

Winston Salem, NC 27157

Phone: 336.716.5992

Fax: 336.716.6275

Office Hours: Monday and Wednesday 8-5

www.wakehealth.edu/cancer/researchbase/

 

CONFIDENTIAL AND PRIVILEGED: The information contained in this electronic message may be privileged and confidential information intended for the sole use of the addressee and any personnel receiving a copy.  If the reader of this electronic message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited.  If you have received this electronic message in error, please notify me immediately by responding to this message.

 

WITHHOLD FROM PUBLIC DISCLOSURE UNDER N.C.G.S. 104E-9(a)(4)

  

  

Quick Reference

Research Base

Fax 336-716-6275
Phone 336-716-0891

2000 West First Street
Protocol Information Office
Suite 101
Winston-Salem, NC 27104
Find A Doctor Ways to Give
Last Updated: 09-10-2014
USNWR 2013-2014Magnet Hospital RecognitionConsumer Choice2014 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.